Compare Asuransi Bintang Tbk (ASBI) vs Dharma Polimetal Tbk. (DRMA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Asuransi Bintang Tbk vs Dharma Polimetal Tbk. — how do they compare? Asuransi Bintang Tbk trades at Rp416 (market cap 142.84B, 1K 24h volume), while Dharma Polimetal Tbk. trades at Rp900 (market cap 4.24T, 1.6M 24h volume). The key difference: Dharma Polimetal Tbk. is far larger — about 29.7× Asuransi Bintang Tbk's market cap, and Dharma Polimetal Tbk. is more actively traded (1.6M versus 1K). Which is the better fit depends on your goals.
| ASBI | DRMA | |
|---|---|---|
Market Cap | 142.84B | 4.24T |
Volume | 1K | 1.6M |
Lot | 10 | 16.04K |
Turnover | 412.6K | 1.45B |
Average Price | 412.6 | 901.1 |
Value | 412.6K | 1.45B |
Indicative Equilibrium Price | — | 900 |
Indicative Equilibrium Volume | — | 200 |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Asuransi Bintang Tbk
PT Asuransi Bintang Tbk (the Company) was established on March 17, 1955 based on Notarial Deed No. 63 of Raden Meester Soewandi, a public notary in Jakarta. The just passing 1999 marked the Bintang's complete 44 service in Indonesia. Along this period, the Company established on March 17th, 1955 has been proving itself as in insurance company persistently holding its commitment. In 1989, Bintang took important step by entering the stock exchange and registered itself at Jakarta and Surabaya Stock Exchange.
Read more on ASBI →About Dharma Polimetal Tbk.
PT Dharma Polimetal Tbk (“the Company”) was established in the Republic of Indonesia on 27 March based on Notarial deed No. 74 of Rukmasanti Hardjasatya, S.H. The Company begin opertions on year 1989 and commenced its commercial activities since 1990. The Company’s Majority shareholder is PT Dharma Inti Anugerah, established in Republic Indonesia on 20 November 2003.
Read more on DRMA →
